Paper · 42981093
Overall Survival in Adults With Acute Myeloid Leukemia Initiating Quizartinib vs Midostaurin With Chemotherapy.
Lee MH and 30 others. JAMA Netw Open, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Overall Survival in Adults With Acute Myeloid Leukemia Initiating Quizartinib vs Midostaurin With Chemotherapy. Papers, record 42981093. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42981093
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Overall Survival in Adults With Acute Myeloid Leukemia Initiating Quizartinib vs Midostaurin With Chemotherapy.
- Journal
- JAMA Netw Open
- Year
- 2026
- Publication types
- Journal Article, Multicenter Study, Comparative Study
- Revised in PubMed
- 2026-11-06
Source PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Phenylurea Compounds | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Benzothiazoles | Major topic |
| Staurosporine | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Female | |
| Retrospective Studies | |
| Male | |
| Middle Aged | |
| fms-Like Tyrosine Kinase 3 | |
| Aged | |
| Adult |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35,797,463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 2 | 29,090,343 | Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). | Ann Hematol | 2017 | https://conductscience.org/library/papers/29090343 | PubMed |
| 3 | 18,064,739 | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. | Lancet | 2007 | https://conductscience.org/library/papers/18064739 | PubMed |
| 4 | 37,581,981 | Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. | Blood Adv | 2023 | https://conductscience.org/library/papers/37581981 | PubMed |
| 5 | 27,908,881 | Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. | Blood | 2017 | https://conductscience.org/library/papers/27908881 | PubMed |
| 6 | 24,002,496 | Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/24002496 | PubMed |
| 7 | 3,457,562 | Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. | Biochem Biophys Res Commun | 1986 | https://conductscience.org/library/papers/3457562 | PubMed |
| 8 | 23,634,996 | Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23634996 | PubMed |
| 9 | 24,141,714 | World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. | JAMA | 2013 | https://conductscience.org/library/papers/24141714 | PubMed |
| 10 | 24,487,413 | Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. | Leukemia | 2014 | https://conductscience.org/library/papers/24487413 | PubMed |
1 to 10 of 34
See all 34 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42981093
GET https://conductscience.org/api/papers/v1/42981093/authors?page=2